Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Deciphering the genomic determinants of CVD
3. CVD: good news and bad news
4. From risk factors to clinical CVD
5. The Framingham heart study
6. Framingham CHD risk algoritm
7. Proposed \emerging \novel risk markers
8. From risk factors to subclinical to clinical CVD
9. From normal heart to clinical disease
10. Environmental and genetic factors
11. Rational for genomic cardiovascular medicine
12. The human euchromatic genome project
13. Genetic variation: 1 SNP \ 1000 bases
14. Haplotypes: informative patterns of DNA variation
15. The haplotype map of the human genome
16. What is genomics?
17. Common DNA variation predisposes to clinical CVD
18. Mendelian vs. complex transmission in MI
19. Prevalence of CHD in risk score positive families
20. Risk of CHD death in 21,004 Swedish twins
21. Risk of offsprings CVD by parental\sibling status
22. Offspring CVD by parental CVD status
23. Heritability of risk factors and subclinical CVD
24. Genomic epidemiology
25. Linkage vs. association
26. Discovering genetic determinants of diseases
27. Quantitative intermediate phenotypes
28. Pogression from risk factors to clinical CVD - detail
29. The electrocardiogram
30. CT and ultrasound imaging
31. Genome-wide linkage analyses for CHD\MI
32. Framingham heart study - three generations
33. Genome-wide linakage for quantitative traits
34. Concepts in selection of CVD candidate genes
35. Single candidate gene variants' studies
36. Why genetic associations may not replicate
37. Use of candidate gene associations
38. Multiple gene variants studies
39. Screening for missense gene variants
40. Magnitudes of risk conferred
41. Gene-based analysis and replication
42. Haplotype approaches for dissecting CVD genetics
43. Hemostatic factor genotyping summary (1)
44. Hemostatic factor genotyping summary (2)
45. Association: htSNPs with PAI-1 levels
46. Risk haplotype'- 4G\5G polymorphism and PAI-1
47. Evolving genomic research approaches
48. Genome-wide studies of up to million gene variants
49. Examples of genome-wide associations studies
50. Common variation in the NOS1 regulator gene
51. Genome-wide scans: population-based cohorts
52. Challenges for genome-wide scans in CVD
53. Sequence variations in PCSK9, low LDL and CVD
54. Sequencing sarcomere genes variants
55. From genome association to genomic medicine
56. Potential translation into genomic medicine
57. MultiSNP approach to disease predication for CHD
58. Design new drugs treatment
59. Personalize treatment
60. Personalize lifestyle
61. Social issues
62. Translating genome-wide findings to clinical practice
63. Evolving concepts in genetic epidemiology

Topics Covered

• Cardiovascular disease (CVD) as the leading cause of death in the Western world
• Role of long-term exposure to risk factors prior to disease manifestation
• Common CVDs: myocardial infarction, stroke, congestive heart failure and sudden cardiac death
• Complex traits with both genetic and environmental risk factors
• The Human Genome Project and the HapMap Project
• Genetic linkage families
• Genome-wide studies of Single Nucleotide Polymorphisms (SNPs)
• Drug development and predictive testing

Links

Series:

• Using Bioinformatics in the Exploration of Genetic Diversity

Categories:

• Genetics & Epigenetics
• Methods

Therapeutic Areas:

• Cardiovascular & Metabolic

Talk Citation

O'Donnell, C. (2007, October 1). Evolving genomic approaches to the study of complex cardiovascular diseases in human populations: genetic and genomic epidemiology [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/AMQX8060.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on May 31, 2018

Financial Disclosures

• Dr. Christopher O'Donnell has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.